Atlasti psu11/14/2022 Through reading and re-reading the data, an analytic framework was developed from the identification of the key issues within the data (using a priori issues and questions from the aims of the study, in addition to issues raised by the participants). AnalysisÄata analysis was undertaken by AC, TR & EW using the framework approach. With permission the interviews were tape-recorded and fully transcribed. Other areas were covered but are not the topic of this paper. An interview guide was used to elicit i) the content of discussions GPs have with asymptomatic men who consult with concerns about prostate cancer/PSA testing and ii) the attitudes of GPs toward the PSA test. Semi-structured telephone interviews were conducted by TR and EW. The key information points are summarised in Table 1. A national information pack was developed to provide guidance for primary care in providing men, who ask their GPs about testing for prostate cancer, with clear and balanced information on the benefits and limitations of testing. Atlasti psu full#Central to this programme is the recommendation that any man who wishes to have a PSA test should have access to the test, provided he has been given full information regarding the possible benefits and limitations associated with receiving a test. However, in response to growing public concern about the disease, in 2001 the Department of Health introduced the Prostate Cancer Risk Management Programme (PCRMP). In the UK, the National Screening Committee has recommended that a prostate cancer screening programme should not be introduced. The PSA test has relatively high false positive and false negative rates, prostate biopsies can miss cancers, and the highly variable nature of prostate cancer means there is potential for diagnosis of indolent cancers that may never present as a problem. There is no strong evidence that screening would result in reduced mortality from the disease. However, there is ongoing debate as to whether screening would result in more harm than good. The high incidence and mortality rates, and the fact that localised disease can potentially be treated, has led to widespread calls for prostate cancer screening. Screening for prostate cancer is controversial. Awareness of the impact of their views on the consultations may help GPs give men a more balanced presentation of the benefits and limitations of the PSA test. Factors specific to PSA testing which appeared to have an impact on the GPs' discussions were the GP's personal opinions of the PSA test, and the need to counter men's primarily positive views of the benefits of PSA testing. The GPs in this study appear to recognise the importance of discussions regarding PSA testing however, a full and balanced picture of the associated advantages and limitations does not seem to be consistently conveyed. Considerable variation existed between GPs in their accounts of the degree of detail given, and GP's presentation of information appeared to be affected by their personal views of the PSA test. They reported less discussion of the potential for diagnosing indolent cancers, the dilemmas regarding treatment options for localised prostate cancer and the potential benefits of testing. They described focussing most of the discussion on the false-positive and false-negative rates of the test, and the risks associated with a prostate biopsy. ResultsĪll GPs reported undertaking some discussion with asymptomatic men about the PSA test. Semi-structured telephone interviews with 21 GPs from 18 GP practices in Oxfordshire. This study aimed to elicit GPs' accounts of their discussions with asymptomatic men who consult with concerns about prostate cancer in order to identify the degree to which the PCRMP guidance was reflected in these consultations. Guidance has been distributed to all GPs in England and Wales to assist in the provision of information to men. The National Health Service Prostate Cancer Risk Management Programme (PCRMP) has recommended that screening for prostate cancer is available for asymptomatic men, on the understanding that they have been provided with full and balanced information about the advantages and limitations of the prostate-specific antigen (PSA) test.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |